Related Experiment Video
Updated: Dec 30, 2025
08:04
Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
Published on: June 6, 2025
1.2K
Modifying genetic epilepsies - Results from studies on tuberous sclerosis complex
Sergiusz Jozwiak1, Katarzyna Kotulska2, Michael Wong3
1Department of Pediatric Neurology, Medical University of Warsaw, Warsaw, Poland.
Neuropharmacology
|January 22, 2020
Summary
Tuberous sclerosis complex (TSC) is a genetic disorder causing epilepsy in 90% of patients. Early intervention in infants with TSC may prevent epilepsy and improve cognitive outcomes.
Area of Science:
- Neurogenetics
- Epileptology
- Developmental Neuroscience
Background:
- Tuberous sclerosis complex (TSC) is an autosomal dominant disorder affecting 1 in 6,000 individuals.
- Epilepsy impacts 90% of TSC patients, often manifesting within the first two years of life.
- Early-onset epilepsy in TSC is linked to cognitive decline and neuropsychiatric issues like autism.
Purpose of the Study:
- To highlight Tuberous sclerosis complex (TSC) as a model for understanding genetic epilepsies.
- To emphasize the role of the mTOR pathway in TSC-related epileptogenesis.
- To discuss the potential of preventive epilepsy treatments in high-risk infants.
Main Methods:
- Review of recent studies on Tuberous sclerosis complex (TSC) and epilepsy.
- Analysis of the mTOR pathway's involvement in epileptogenesis.
- Evaluation of evidence for early, disease-modifying epilepsy treatments.
Main Results:
- Recent studies show positive effects of preventive epilepsy treatment in high-risk infants.
- These treatments are associated with a lower incidence of epilepsy.
- Improved cognitive outcomes have been observed in infants receiving early intervention.
Conclusions:
- Tuberous sclerosis complex (TSC) serves as a crucial model for genetic epilepsy research.
- Targeting the dysregulated mTOR pathway holds therapeutic potential.
- Further research into preventive epilepsy treatments for early childhood genetic epilepsies is warranted.
Related Concept Videos
01:24Epilepsy and Seizures: Overview
1.1K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
1.1K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.1K